Older studies estimated a lower risk of dementia. According to new research, the number of people living with the disease in ...

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

Gryphon Bio, Inc. has announced its pursuit of observational clinical studies with partners at multiple U.S. and international clinical sites to demonstrate the benefits of a novel panel of blood ...

Delray Medical Center cut the ribbon on its newest high-tech machine last week that targets brain areas to treat movement ...

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...

Delirium is characterized by an acute change in cognition, accompanied by either altered consciousness or disorganized ...

Spanish drugmaker Grifols has been awarded a $21 million grant from the Michael J Fox Foundation to support a pilot study to ...

IgG MoDE Degraders: BHV-1300 Phase 1 completing last remaining dose cohorts with the optimized subcutaneous formulation with expected completion in 1H 2025. BHV-1310 first-in-human study anticipated ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...